A61K 40/4256
Tumor associated carbohydrates
Official title: {Tumor associated carbohydrates}
A61K40/4256 (Tumor associated carbohydrates) appears on 202 US grants and 478 published applications in this corpus.
Search patents in A61K- Granted patents
- 202
- Published applications
- 478
- Assignees
- 185
- Inventors
- 795
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 6 |
| 2003 | 2 | 2 |
| 2004 | 1 | 4 |
| 2005 | 0 | 2 |
| 2006 | 1 | 3 |
| 2007 | 0 | 3 |
| 2008 | 0 | 5 |
| 2009 | 2 | 5 |
| 2010 | 2 | 3 |
| 2011 | 2 | 5 |
| 2012 | 3 | 3 |
| 2013 | 2 | 5 |
| 2014 | 1 | 11 |
| 2015 | 5 | 3 |
| 2016 | 8 | 9 |
| 2017 | 5 | 17 |
| 2018 | 8 | 18 |
| 2019 | 7 | 32 |
| 2020 | 15 | 44 |
| 2021 | 17 | 60 |
| 2022 | 18 | 47 |
| 2023 | 22 | 45 |
| 2024 | 19 | 67 |
| 2025 | 32 | 50 |
| 2026 | 28 | 29 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Anti-MUC1-C antibodies and CAR-T structures15 Sep 2026US 12,735,503 B2TeneoBio, Inc.
- Compositions and methods for inhibiting T cell exhaustion8 Sep 2026US 12,729,245 B2The Board of Trustees of the Leland Stanford Junior University
- Methods and compositions for chimeric antigen receptor targeting cancer cells1 Sep 2026US 12,721,892 B2The University of North Carolina at Chapel Hill
- Presenting cell and use thereof in cell therapy11 Aug 2026US 12,702,708 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Modulation of b-cell translocation gene 1 (btg1) for use in adoptive cell therapy1 Oct 2026US 2026/0294968 A1Baylor College of Medicine
- Method for the production of bi-functional cells to treat neoplasia1 Oct 2026US 2026/0297162 A1Eir Biotherapies Srl
- SIRPalpha Knockout iPSC-derived and CAR-comprising Macrophages with Enhanced Anti-tumor Activity24 Sep 2026US 2026/0284104 A1Wisconsin Alumni Research Foundation
- Methods and materials for treating cancer24 Sep 2026US 2026/0284192 A1Mayo Foundation for Medical Education and Research
- Plasmacytoid dendritic cells for treating cancer17 Sep 2026US 2026/0272977 A1Pdc Line Pharma
Most cited
By later US patents
- Compositions, methods, and computer systems related to making and administering modified T cells107US 9,499,855 B2Elwha LLC · 2016
- Method for proliferation of antigen-specific T cells54US 9,476,028 B2Immunicum AB · 2016
- Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen46US 7,655,461 B2University of Pittsbugh — Of the Commonwealth System of Higher Education · 2010
- Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-139US 7,999,071 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Lipid-modified muc-1 derivatives28US 6,600,012 B1Biomira, Inc. · 2003